TY  - GEN
AU  - García-Cárceles, Javier
AU  - Vázquez-Villa, Henar
AU  - Brea, José
AU  - Ladron de Guevara-Miranda, David
AU  - Cincilla, Giovanni
AU  - Sánchez-Martínez, Melchor
AU  - Sánchez-Merino, Anabel
AU  - Algar, Sergio
AU  - Teresa de Los Frailes, María
AU  - Roberts, Richard S
AU  - Ballesteros, Juan A
AU  - Rodríguez de Fonseca, Fernando
AU  - Benhamú, Bellinda
AU  - Loza, María I
AU  - López-Rodríguez, María L
PY  - 2022
DO  - 10.1021/acs.jmedchem.2c00949
UR  - http://hdl.handle.net/20.500.12105/18754
AB  - Tolerance development caused by dopamine replacement with l-DOPA and therapeutic drawbacks upon activation of dopaminergic receptors with orthosteric agonists reveal a significant unmet need for safe and effective treatment of Parkinson's disease. In...
LA  - eng
KW  - Animals
KW  - Biphenyl Compounds
KW  - Cocaine
KW  - Dopamine
KW  - Dopamine Agents
KW  - Dopamine Agonists
KW  - Humans
KW  - Indazoles
KW  - Levodopa
KW  - Ligands
KW  - Mice
KW  - Nitrofurans
KW  - Parkinson Disease
KW  - Receptors, Dopamine
KW  - Receptors, Dopamine D1
TI  - 2-(Fluoromethoxy)-4'-(S-methanesulfonimidoyl)-1,1'-biphenyl (UCM-1306), an Orally Bioavailable Positive Allosteric Modulator of the Human Dopamine D1 Receptor for Parkinson's Disease.
TY  - research article
ER  -